Table 1 Clinical cardiac and laboratory findings for aged vervet monkeys and cynomolgus monkeys

From: Aged vervet monkeys developing transthyretin amyloidosis with the human disease-causing Ile122 allele: a valid pathological model of the human disease

Case no.

Age (years)

Sex

Living conditions

BW (kg)

Clinical findings

IVSd (mm)

LVPWd (mm)

EF (%)

FS (%)

Plasma ANP concentrations (pg/ml)

TTR amyloid deposits

V1

8

F

E

2.85

Normal cardiac function, CTR: 51%

0.44

0.38

78.4

44.1

19.0

NE

V2

14

F

E

3.35

Heart enlargement, reduced ventricular wall motion

0.67

0.43

48.8

23.2

41.0

NE

V3

15

F

E

3.10

Normal cardiac function

0.28

0.40

69.9

35.8

9.3

NE

V4

15

F

E

2.95

Normal cardiac function

0.45

0.66

81.6

46.3

16.1

NE

V5

15

F

E

2.70

Arrhythmia, heart enlargement, reduced ventricular wall motion, CTR: 67%

0.57

0.52

32.5

14.2

133.0

NE

V6

17

M

E

4.80

Arrhythmia

0.29

1.12

58.3

27.9

10.9

NE

V7

17

M

E

4.40

Arrhythmia, heart enlargement, reduced ventricular wall motion, CTR: 64%

0.44

0.84

45.8

20.9

50.4

NE

V8

17

F

E

NE

Normal cardiac function, uterine myoma

0.63

0.44

78.2

43.0

<5.0

−

V9

17

F

E

4.00

Normal cardiac function

0.43

0.35

67.8

34.9

11.1

NE

V10

18

F

E

2.75

Normal cardiac function

0.61

0.73

69.9

35.9

33.5

NE

V11

20

M

E

5.00

Heart enlargement, reduced ventricular wall motion, CTR: 63%

0.37

0.70

35.4

15.9

14.6

NE

V12

20

F

E

4.45

Arrhythmia

0.70

0.55

64.3

32.5

19.2

NE

V13

25

M

E

NE

NE

NE

NE

NE

NE

NE

−

V14a

26

M

Z

3.70

Cardiac failure (shortness of breath)

NE

NE

NE

NE

NE

+

V15

27

M

E

3.95

Arrhythmia, thoracic tumor

0.71

0.61

65.0

32.9

64.2

+

V16b

29

M

E

NE

Arrhythmia, CTR: 68%

NE

NE

NE

NE

44.7

+

V17

>30

F

E

NE

NE

NE

NE

NE

NE

NE

−

C1

1

F

E

1.50

Normal cardiac function

0.46

0.51

77.6

42.0

NE

NE

C2

1

F

E

2.12

Normal cardiac function

0.32

0.46

68.1

34.5

NE

NE

C3

4

M

E

NE

Normal cardiac function

0.36

0.68

60.6

28.9

NE

−

C4

4

M

E

4.53

Normal cardiac function

0.52

0.60

65.6

33.4

NE

NE

C5

6

M

E

NE

Normal cardiac function

0.45

0.63

61.7

30.7

NE

−

C6

7

F

E

NE

Normal cardiac function

0.48

0.61

65.9

33.3

NE

−

C7

9

F

E

3.34

Normal cardiac function

0.36

0.40

63.4

31.6

NE

NE

C8

9

F

E

3.22

Normal cardiac function

0.38

0.38

74.8

41.9

NE

NE

C9

10

M

E

6.21

Normal cardiac function

0.49

0.67

64.8

33.3

NE

NE

C10

16

F

E

2.89

Normal cardiac function

0.57

0.75

79.9

44.3

NE

NE

C11

20

M

E

5.00

Normal cardiac function

0.39

0.53

81.3

45.7

NE

−

C12

21

F

E

3.16

Normal cardiac function

0.44

0.58

84.7

49.2

NE

NE

C13

22

M

E

5.78

Normal cardiac function

0.37

0.47

74.4

39.8

NE

−

C14

23

F

E

5.77

Normal cardiac function

0.28

0.28

71.0

38.4

NE

NE

C15

24

M

E

5.68

Normal cardiac function

0.67

0.78

77.5

43.3

NE

−

C16

24

M

E

6.54

Normal cardiac function

0.75

0.80

76.1

41.6

NE

−

C17

25

M

E

7.12

Normal cardiac function

0.61

0.72

60.7

30.2

NE

−

  1. Abbreviations: BW, body weight; C, cynomolgus monkey; CTR, cardiothoracic ratio; E, living in captivity in an experimental facility (the Tsukuba Primate Research Center for Medical Science at the National Institute of Biomedical Innovation); EF, ejection fraction; F, female; FS, fractional shortening; IVSd, interventricular septal thickness in diastole; LVPWd, left ventricular posterior wall thickness in diastole; M, male; NE, not examined; V, vervet monkey; Z, living in captivity in a zoo.
  2. aWe previously reported details of case no. V14.15
  3. bWe also previously reported details of case no. V16.14 Underlined bold type indicates abnormal data.
Back to article page